Leman Biotech has been granted approval from the First Affiliated Hospital of University of Science and Technology of China to conduct an Investigator-Initiated Trial (IIT) clinical study of Meta10-19 injection for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) (NCT05715606). The company has now announced the recruitment of patients for this study.
Meta10-19 injection, a novel CAR-T product developed by Leman Biotech, a breakthrough metabolic reprogramming technology originated from the Swiss Federal Institute of Technology Lausanne (EPFL). Preclinical studies have demonstrated that Meta10-19 CAR-T cells exhibit superior resistance to exhaustion and generate a stem cell-like memory phenotype, leading to complete tumor clearance and effective prevention of recurrence in mouse tumor models. These promising preclinical findings suggest that Meta10-19 CAR-T could significantly improve the complete response rate (CR) and reduce the recurrence rate, offering new hope for the treatment of hematological malignancies.
Key eligibility criteria for participation in this study include being over 18 years old, demonstrating positive CD19 expression, and having a diagnosis of relapsed or refractory diffuse large B-cell lymphoma. Patients who have experienced relapse after poor response or complete remission with conventional CAR-T therapy are also eligible. Further enrollment requirements can be obtained by consulting with healthcare professionals.
Interested individuals can contact the designated doctors directly or visit the Bone Marrow Transplantation Center, Department of Hematology, Anhui Provincial Hospital, for more information. Upon screening and enrollment, participants will receive free Meta10-19 injection and regular observation and follow-up by medical professionals.
Lead Investigator: Director Wang, Department of Hematology
Contact Number: 138 5600 7984
Clinic Hours: Monday morning (Anhui Provincial Hospital South Area), Tuesday afternoon, and Wednesday morning (Anhui Provincial Hospital General Hospital)
Researcher: Director Xue, Department of Hematology
Tel: 135 1564 3807
Address: Department of Hematology, Anhui Provincial Hospital South Area, No. 1 Swan Lake Road, Hefei, Anhui Province, China
